Found 10 bookmarks
Newest
Frontiers | Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study
Frontiers | Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study

A study in Guangzhou, China, with 248 COVID-19 patients found that Paxlovid is effective and safe when given within 10 days of onset, reducing viral load

Effectiveness decreases after 10 days, but multiple cycles may help if the viral load remains high

·frontiersin.org·
Frontiers | Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study
Two papers that convinced me that the best early treatment for COVID is sunlight and why (a thread):
Two papers that convinced me that the best early treatment for COVID is sunlight and why (a thread):

“Two papers that convinced me that the best early treatment for COVID is sunlight and why (a thread):

Sunlight's photons are more than 50% infrared. Infrared light passes through the body very easily (even through bone). As seen in this picture:”

·x.com·
Two papers that convinced me that the best early treatment for COVID is sunlight and why (a thread):
Berberine reduces circulating inflammatory mediators in patients with severe COVID-19 | British Journal of Surgery | Oxford Academic
Berberine reduces circulating inflammatory mediators in patients with severe COVID-19 | British Journal of Surgery | Oxford Academic
Berberine is 18 times more potent than Metformin in killing SARS-Cov-2, 1.5 times more potent than paxlovid. Berberine powerfully mitigates inflammatory cascade responses to SARS-Cov-2
·academic.oup.com·
Berberine reduces circulating inflammatory mediators in patients with severe COVID-19 | British Journal of Surgery | Oxford Academic
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial

Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.

Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.
·thelancet.com·
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
laurie allee on Twitter
laurie allee on Twitter

Rabbit hole: I’m starting a thread on early Covid treatment/management strategies around the world. (I have a separate thread for different world vaccines.)

You’ll need Google translate. 👇🏻

·twitter.com·
laurie allee on Twitter